Compare EXLS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXLS | NUVL |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.1B |
| IPO Year | 2006 | 2021 |
| Metric | EXLS | NUVL |
|---|---|---|
| Price | $41.31 | $104.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $54.50 | ★ $134.29 |
| AVG Volume (30 Days) | ★ 1.1M | 828.0K |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.94 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $2,026,490,000.00 | N/A |
| Revenue This Year | $15.27 | N/A |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $28.13 | ★ N/A |
| Revenue Growth | ★ 14.43 | N/A |
| 52 Week Low | $37.30 | $55.54 |
| 52 Week High | $52.43 | $112.88 |
| Indicator | EXLS | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 51.80 |
| Support Level | $39.84 | $103.52 |
| Resistance Level | $42.03 | $107.99 |
| Average True Range (ATR) | 0.72 | 3.17 |
| MACD | 0.23 | -0.94 |
| Stochastic Oscillator | 72.48 | 10.02 |
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.